Advancing stroke therapy: innovative approaches with stem cell-derived extracellular vesicles.
Jiahao SongRan MengLili CuiChuanjie WuLina JiaMengqi WangJingrun LiJingyuan YaXunming JiRan MengPublished in: Cell communication and signaling : CCS (2024)
Stroke is a leading cause of mortality and long-term disability globally, with acute ischemic stroke (AIS) being the most common subtype. Despite significant advances in reperfusion therapies, their limited time window and associated risks underscore the necessity for novel treatment strategies. Stem cell-derived extracellular vesicles (EVs) have emerged as a promising therapeutic approach due to their ability to modulate the post-stroke microenvironment and facilitate neuroprotection and neurorestoration. This review synthesizes current research on the therapeutic potential of stem cell-derived EVs in AIS, focusing on their origin, biogenesis, mechanisms of action, and strategies for enhancing their targeting capacity and therapeutic efficacy. Additionally, we explore innovative combination therapies and discuss both the challenges and prospects of EV-based treatments. Our findings reveal that stem cell-derived EVs exhibit diverse therapeutic effects in AIS, such as promoting neuronal survival, diminishing neuroinflammation, protecting the blood-brain barrier, and enhancing angiogenesis and neurogenesis. Various strategies, including targeting modifications and cargo modifications, have been developed to improve the efficacy of EVs. Combining EVs with other treatments, such as reperfusion therapy, stem cell transplantation, nanomedicine, and gut microbiome modulation, holds great promise for improving stroke outcomes. However, challenges such as the heterogeneity of EVs and the need for standardized protocols for EV production and quality control remain to be addressed. Stem cell-derived EVs represent a novel therapeutic avenue for AIS, offering the potential to address the limitations of current treatments. Further research is needed to optimize EV-based therapies and translate their benefits to clinical practice, with an emphasis on ensuring safety, overcoming regulatory hurdles, and enhancing the specificity and efficacy of EV delivery to target tissues.
Keyphrases
- cerebral ischemia
- acute ischemic stroke
- stem cell transplantation
- subarachnoid hemorrhage
- stem cells
- blood brain barrier
- brain injury
- quality control
- atrial fibrillation
- clinical practice
- cancer therapy
- high dose
- single cell
- gene expression
- multiple sclerosis
- human health
- heart failure
- risk assessment
- type diabetes
- climate change
- dna methylation
- cardiovascular disease
- deep learning
- endothelial cells
- low dose
- insulin resistance
- cardiovascular events
- left ventricular
- bone marrow
- cell therapy
- replacement therapy